PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26223F0041Krystexxa pegloticase to TREAT patients at — Horizon Therapeutics Usa, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 19, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)
Awarding office
Horizon Therapeutics Usa, Inc
Recipient
Oct 19, 2023
PoP end
$591K
Obligated
$861K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Horizon Therapeutics Usa, Inc — $90

Contract facts

Federal
Contract number36C26223F0041
Also listed as36C262-23-F-0041
Also listed as36F79719D0224-36C26223F0041
Agency262-Network Contract Office 22 (36C262)
Awarding office262-Network Contract Office 22 (36C262)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentHorizon Therapeutics Usa, Inc
CAGE6TDL9
UEISK1UK7S74GB3
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79719D0224
Place of performanceLA VERGNE TN
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
Related solicitation36C26222Q1761
PoP startOct 20, 2022
PoP end (current)Oct 19, 2023
Obligated$591K
Current value$861K
Potential value$861K

KRYSTEXXA PEGLOTICASE TO TREAT PATIENTS AT VASDHCS is a federal award for 262-Network Contract Office 22 (36C262) held by Horizon Therapeutics Usa, Inc. Estimated value $861K ($591K obligated). Current period of performance ends Oct 19, 2023. Last award drew 1 bidder. Place of performance: LA VERGNE TN. Related solicitation 36C26222Q1761.

KRYSTEXXA PEGLOTICASE TO TREAT PATIENTS AT VASDHCS

Recompete timing

Public
Past PoP end (1037 days ago)

Current PoP ended Oct 19, 2023 (1037 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract 36C26223F0041?

36C26223F0041 (Krystexxa pegloticase to TREAT patients at) is a 262-Network Contract Office 22 (36C262) award with a potential value of $861K, currently held by Horizon Therapeutics Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-23-F-0041?

36C262-23-F-0041 is the dashed form of PIID 36C26223F0041 (Krystexxa pegloticase to TREAT patients at), held by Horizon Therapeutics Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26223F0041?

262-Network Contract Office 22 (36C262) awarded 36C26223F0041 to Horizon Therapeutics Usa, Inc (potential $861K).

Who is the incumbent on 36C26223F0041?

Horizon Therapeutics Usa, Inc is the incumbent. The current period of performance ends Oct 19, 2023.

When does Horizon Therapeutics Usa, Inc’s 36C26223F0041 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 19, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C26223F0041